Galantamine as a Treatment Option for Nicotine Addiction | Zendy

Qutub Jamali | Zendy; Renée Bittoun | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Galantamine as a Treatment Option for Nicotine Addiction

Author(s) -

Qutub Jamali,

Renée Bittoun

Publication year - 2021

Publication title -

the journal of smoking cessation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.25

H-Index - 15

ISSN - 1834-2612

DOI - 10.1155/2021/9975811

Subject(s) - varenicline , galantamine , medicine , smoking cessation , nicotine , bupropion , pharmacology , partial agonist , nicotine replacement therapy , agonist , nasal spray , psychiatry , donepezil , nasal administration , dementia , receptor , disease , pathology

The pharmacological therapy for smoking cessation recommended by National Institute for Health and care Excellence (NICE) guidelines is nicotine replacement therapy such as gum, inhalator, lozenge, nasal spray, oral spray, sublingual tablet, and transdermal patch. Medications such as bupropion and varenicline are also used. Varenicline is the only established drug used to alleviate symptoms of craving as it acts as a partial nicotine agonist. Galantamine has a similar mechanism of action where it is an acetylcholinesterase inhibitor and nicotinic receptor agonist. However, varenicline is the only recommended drug. There are not many studies to illustrate the effectiveness of galantamine for smoking cessation. This article explores the possibility of potential use of galantamine in alleviating the symptoms of nicotine withdrawal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research